| 4.9999 0.25 (5.26%) | 09-19 11:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.36 |
1-year : | 7.43 |
| Resists | First : | 5.44 |
Second : | 6.36 |
| Pivot price | 5.1 |
|||
| Supports | First : | 4.61 |
Second : | 4.09 |
| MAs | MA(5) : | 4.91 |
MA(20) : | 5.11 |
| MA(100) : | 5.23 |
MA(250) : | 5.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.5 |
D(3) : | 48.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 6.98 | Low : | 4.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLGN ] has closed above bottom band by 37.7%. Bollinger Bands are 5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.88 - 4.92 | 4.92 - 4.94 |
| Low: | 4.59 - 4.63 | 4.63 - 4.66 |
| Close: | 4.71 - 4.78 | 4.78 - 4.82 |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Mon, 16 Sep 2024
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest - MarketBeat
Wed, 21 Aug 2024
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants - Yahoo Finance
Tue, 20 Aug 2024
CollPlant Announces Upcoming Shareholder Meeting - TipRanks
Tue, 20 Aug 2024
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
Tue, 20 Aug 2024
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call Transcript - MSN
Mon, 19 Aug 2024
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.82e+006 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.731e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 769.4 % |
| Return on Equity (ttm) | -33.8 % |
| Qtrly Rev. Growth | 689000 % |
| Gross Profit (p.s.) | -212.18 |
| Sales Per Share | -133.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 1.27 |
| Dividend | 0 |
| Forward Dividend | 9370 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|